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ttp://dx.doi.org/10.1016/j.ajpath.2013.08.004Loss of miR-122 causes chronic steatohepatitis and spontaneous hepatocellular carcinoma. However,
the consequence of miR-122 deﬁciency on genotoxic stresseinduced liver pathogenesis is poorly un-
derstood. Here, we investigated the impact of miR-122 depletion on liver pathobiology by treating
liver-speciﬁc miR-122 knockout (LKO) mice with the hepatocarcinogen diethylnitrosamine (DEN). At 25
weeks post-DEN injection, all LKO mice developed CK-19epositive hepatobiliary cysts, which correlated
with DEN-induced transcriptional activation of Cdc25a mediated through E2f1. Additionally, LKO livers
were more ﬁbrotic and vascular, and developed larger microscopic tumors, possibly due to elevation of
the Axl oncogene, a receptor tyrosine kinase as a novel target of miR-122, and several protumorigenic
miR-122 targets. At 35 weeks following DEN exposure, LKO mice exhibited a higher incidence of
macroscopic liver tumors (71%) and cysts (86%) compared to a 21.4% and 0% incidence of tumors and
cysts, respectively, in control mice. The tumors in LKO mice were bigger (ninefold, P Z 0.015) and
predominantly hepatocellular carcinoma, whereas control mice mostly developed hepatocellular ade-
noma. DEN treatment also reduced survival of LKO mice compared to control mice (P Z 0.03).
Interestingly, induction of oxidative stress and proinﬂammatory cytokines in LKO liver shortly after DEN
exposure indicates predisposition of a pro-tumorigenic microenvironment. Collectively, miR-122
depletion facilitates cystogenesis and hepatocarcinogenesis in mice on DEN challenge by up-
regulating several genes involved in proliferation, growth factor signaling, neovascularization, and
metastasis. (Am J Pathol 2013, 183: 1719e1730; http://dx.doi.org/10.1016/j.ajpath.2013.08.004)Supported by NIH grants DK088076 and CA086978 (K.G.).Hepatocellular carcinoma (HCC) is the most common liver
cancer, and the ﬁfth most prevalent cancer worldwide. Its
incidence has almost tripled in the United States during the
past 20 years.1,2 Almost all HCC arises in patients with
chronic liver disease and cirrhosis. The difﬁculties in early
diagnosis and the lack of effective therapy are responsible
for the fast-growing mortality of HCC patients. Therefore,
development of novel biomarkers for early detection and a
therapeutic strategy to treat this deadly disease in a timely
manner are urgently needed. Although the major risk factor
leading to HCC is hepatitis B and C virus infection, alco-
holic and nonalcoholic fatty liver disease are emerging asstigative Pathology.
.important risk factors for HCC.3 Additionally, genetic mu-
tations, such as hemochromatosis, a-1-antitrypsin deﬁciency,
and environmental toxins such as aﬂatoxin B1 and vinyl
chloride also cause liver cancer. It is, therefore, important to
investigate the impact of speciﬁc gene/environment in-
teractions on hepatocarcinogenesis because disruption of
speciﬁc genes can profoundly inﬂuence the response of an
organism to genotoxic insults.
miR-122 is an abundant liver-speciﬁc miRNA that is
conserved in vertebrates.4 miR-122 is transcribed as an
Hsu et alapproximately 7.5-kiloneucleotide (knt) primary transcript
from an intergenic region, which is subsequently processed
to 66-nt precursor RNA and approximately 22-nt mature
miR-122. Hepatocyte-speciﬁc transcription of miR-122 is
regulated by liver-enriched transcription factors such as
hepatocyte nuclear factor-1-a (HNF1a), HNF3a/b,5
HNF4,6 and HNF6.7 Interestingly, the expression of the
primary transcript, but not the mature miR-122, oscillates
with diurnal rhythm regulated by the repressor Rev-erbA.8
Stabilization of mature miR-122 by the addition of a sin-
gle adenosine to its 30-end by GLD2, a noncanonical cyto-
plasmic poly(A) polymerase,9 is likely to cause its high
abundance.
miR-122 is one of the most widely studied miRNAs.4
Several seminal discoveries were made while studying its
physiological function, HCV viral infection, and cancer.
miR-122 was successfully depleted in the livers of mice by
injecting antagomir, a cholesterol-conjugated, phosphor-
othioate-modiﬁed antisense oligonucleotide, through the tail
vein, which resulted in hypocholesterolemia,10 suggesting its
potential use in the treatment of atherosclerosis. Another
unique function of miR-122 is its role in aiding HCV repli-
cation in hepatocytes. Because of the high abundance of miR-
122 only in the liver, HCV virus can propagate only in liver,
causing hepatitis, which often leads to HCC. Miravirsen, a
locked nucleic acidemodiﬁed 15-mer antiemiR-122 oligo-
nucleotide, is the ﬁrst miRNA-based therapy currently un-
dergoing clinical trials in reducing viremia in HCV-infected
patients. However, several studies have shown that pro-
longed depletion of miR-122 can cause deleterious effects on
liver functions. First, miR-122 was down-regulated in pri-
mary HCC of both rodent and human origin,11 which
correlated with poor prognosis, metastasis, and dedifferen-
tiation of hepatocytes.5 Second, miR-122 exhibited tumor
suppressor function when ectopically expressed in HCC cell
lines.12,13 Third, miravirsen-mediated depletion of miR-122
caused systemic iron deﬁciency in adult mice.14 Finally,
progressive development of hepatitis, steatosis, and ﬁbrosis
in liver-speciﬁc and germline miR-122 knockout mice re-
inforces its essential role in maintaining liver function.15,16
Furthermore, occurrence of spontaneous liver tumors in
approximately 50% of the male mice after 12 months, and
profound reduction of liver tumor growth after delivery of the
miR-122 precursor gene15 or miR-122 mimic12,17 in mice
conﬁrmed its tumor suppressor function, and suggested that
prolonged depletion of miR-122 in HCC patients might have
deleterious consequences. These observations revealed that
this miRNA is not essential for liver development, although it
performs diverse functions in the liver.
In the present study, we investigated susceptibility of
liver-speciﬁc miR-122 knockout (LKO) mice to diethylni-
trosamine (DEN), the most frequently used carcinogen that
promotes liver tumors in rodents. The results show that the
loss of hepatic miR-122 predisposes mice to develop liver
cysts and HCCs within 8 months on challenge with this
hepatocarcinogen during the neonatal stage.1720Materials and Methods
Mice
LKOmiceweregeneratedby crossingﬂoxed (miR-122loxP/loxP)
mice with transgenic Alb-Cremice, obtained from the Jackson
Laboratory (Bar Harbor, ME).15 The mice were housed in
barrier facilities and fed chow diet. All mice were housed,
handled, and euthanized in accordance with NIH and institu-
tional guidelines of The Ohio State University Institutional
Animal Care and Use Committee.
DEN-Induced Primary Tumor Model
Liver tumors were induced in miR-122 LKO and ﬂoxed
littermate (control) mice on a C57BL6 background by a
single DEN injection (25 mg/kg body weight) on postnatal
day 14 (P14), following published protocol,18 and were
sacriﬁced at speciﬁed time points post-DEN injection.
Saline-injected mice were used as controls. Body weight,
liver and tumor weights, and the tumor number were docu-
mented, and sera were collected.
Histological and Serological Analysis
H&E and Sirius Red staining of tissue sections were per-
formed as described.19 The scoring of inﬂammation and
steatosis was performed on H&E-stained sections (100
magniﬁcation) using the following criteria: 0, no inﬂam-
mation; 1, mild lymphocytic inﬁltration in the portal triad; 2,
severe lymphocytic inﬁltration in the portal triad; and 3,
extended inﬁltration of lymphocytes throughout liver.
Serology was performed as described.15
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded sections were subjected to
immunohistochemistry (IHC) for Ki-67, cytokeratin-19
(CK-19), a-fetoprotein (Afp), and bromodeoxyuridine (BrdU)
incorporation as described.15,18 The antibodies used for IHC
were as follows: rabbit antieKi-67 (ab-15580; Abcam,
Cambridge, MA); rabbit anti-CK19 (a generous gift from Dr.
Joshua Freeman)20; mouse anti-Afp (AF5369; R&D Systems,
Minneapolis, MN), and mouse anti-BrdU (B8434; Sigma-
Aldrich, St. Louis, MO). Ki-67epositive cells were counted
in ﬁve randomly selected ﬁelds at 400 magniﬁcation, typi-
cally containing approximately 90 to 110 hepatocytes.
MRI
Magnetic resonance imaging (MRI) of liver tumors in mice
was performed as described.21
Northern Blot Analysis and TaqMan Assay
Northern blot analysis and TaqMan (Life Technologies,
Carlsbad, CA) assay of miR-122 were as described.12ajp.amjpathol.org - The American Journal of Pathology
Table 1 Primers for Real-Time RT-qPCR
Name Sequence
IL6 RTForward 50-AGACTTCACAGAGGATACCACTCCC-30
IL6 RTReverse 50-TCTCATTTCCACGATTTCCCAG-30
Tnfa RTForward 50-ACCGTCAGCCGATTTGCTATC-30
Tnfa RTReverse 50-TCAGAGTAAAGGGGTCAGAGTGGG-30
IL1b RTForward 50-AAAAAAGCCTCGTGCTGTCG-30
IL1b RTReverse 50-GTCGTTGCTTGGTTCTCCTTG-30
mAxl RTForward 50-CATTGCCAAGATGCCAGTCAAG-30
mAxl RTReverse 50-CCACATTGTCACACCGAAGGAC-30
hAxl RTForward 50-ACCTTCAACTCCTGCCTTCTCG-30
hAxl RTReverse 50-TAACGGGTCTCCTTCTTTCGCC-30
Gapdh RTForward 50-TCCTGCACCACCAACTGCTTAG-30
Gapdh RTReverse 50-TGCTTCACCACCTTCTTGATGTC-30
Cdc25a RTForward 50-ATGGCTTCATAGACCTTCTGGATG-30
Cdc25a RTReverse 50-TGGGCACACTCTTCCTCCTCTTTG-30
Cdc25a hnRNA
RTForward
50-CACGGGGAAGATGCTGTTTG-30
Cdc25a hnRNA
RTReverse
50-TCTGTTTCCTGCTGGATCATCC-30
E2f1 RTForward 50-TGACGGTGTCGTTGACCTGAAC-30
E2f1 RTReverse 50-CTTGGACTTCTTGGCAATGAGC-30
c-Jun RTForward 50-TGGGCACATCACCACTACACC-30
c-Jun RTReverse 50-GGTTGAAGTTGCTGAGGTTGGC-30
Adam10 RTForward 50-GCTGGGAGGTCAGTATGGAAATC-30
Adam10 RTReverse 50-TGGCACGCTGGTGTTTTTGG-30
Epcam RTForward 50-GATGAAAAGGCACCCGAGTTC-30
Epcam RTReverse 50-TAACCAGGACAACAATCCCCGC-30
Ctnnb1 RTForward 50-GCTGGTGAAAATGCTTGGGTC-30
Ctnnb1 RTReverse 50-GCTTGCTCTCTTGATTGCCATAAG-30
Igf2 RTForward 50-CCTGGAGACATACTGTGCCACC-30
Igf2 RTReverse 50-TTGGAAGAACTTGCCCACGG-30
Mapkapk2
RTForward
50-CATCACCGACGACTACAAGGTCAC-30
Mapkapk2
RTReverse
50-GACAATCAGCAGGCACTTCCTC-30
Ndrg3 RTForward 50-GGCTTACCAAAAGGAAACAGACC-30
Ndrg3 RTReverse 50-GTGAGAACAGGAGGCAGCATC-30
Tgfb RTForward 50-CCAACTATTGCTTCAGCTCC-30
Tgfb RTReverse 50-GGTCCAGGCTCCAAAT-30
Vegf RTForward 50-GATCATGCGGATCAAACCTCACC-30
Vegf RTReverse 50-TTTACACGTCTGCGGATCTTGGAC-30
Vimentin RTForward 50-GATGTTGACAATGCTTCTCTGGC-30
Vimentin RTReverse 50-ATGCTGTTCCTGAATCTGGGC-30
Ctgf RTForward 50-CACCAGTGTGAAGACATACAGGGC-30
Ctgf RTReverse 50-TCGGGGCATTTGAACTCCAC-30
DEN Induces Liver Cyst in miR122 LKOWestern Blot Analysis
Proteins were extracted from liver tissues in the lysis buffer
containing protease and phosphatase inhibitor cocktails as
described,15 and 50 to 100 mg of proteins were subjected to
Western blot analysis with speciﬁc antibodies. Catalog
numbers and companies of antibodies used are provided as
follows: from Santa Cruz Biotechnology (Dallas, TX): anti-
Adam10 (sc-28358), anti-Afp (sc-8108), anti-Axl (sc-1096),
anti-Ccng1 (sc-718), anti-Cdc25a (sc-7389), anti-E2f1 (sc-
193), and anti-Srf (sc-335); from Millipore (Billerica, MA):
anti-Gapdh (MAB374).
Real-Time RT-qPCR
Real-time quantitative RT-PCR (RT-qPCR) analysis of
mRNAs was performed using SYBR Green chemistry (Life
Technologies). Relative expression was calculated using the
DDCTmethod.
22 Theprimer sequences are provided in Table 1.
30-Untranslated Region Cloning and Luciferase
Reporter Assay
30-Untranslated regions (UTRs) of Axl and Cdc25a spanning
miR-122 cognate sites were ampliﬁed from genomic DNA
using speciﬁc primers and were cloned into psiCHECK2
vector. Transfection of the reporter with miR-122 mimic or
negative control RNA and luciferase assays were performed as
described.15 The primer sequences are provided as follows:
Axl-30-UTR XhoI forward, 50-CCGCTCGAGTGAGACA-
ATCTTCCACCTGGGAC-30; Axl-30-UTR NotI reverse, 50-
ATAAGAATGCGGCCGCGGTGTCCAGCATTAGAAGT-
GGTTAG-30; Axl del 30-UTR XhoI forward, 50-CCGCTCG-
AGACATCTTCCATCCCAGCGTTC-30; Cdc25a-30-UTR
XhoI forward, 50-CCGCTCGAGAAGACCTAAAGAAGT-
TCCGCAC-30; Cdc25a-30UTR NotI reverse, 50-AAGAATG-
CGGCCGCTGCCCACCCAACACTGATTG-30; Cdc25a-del
30-UTR XhoI forward, 50-CCGCTCGAGCCGTTACACT-
CTTCTGTTCTG-30.
Transfection of E2f1 siRNA
Hepa cells cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% fetal bovine serum were transfected with 60
nmol/L E2f1 siRNA (M-044993-03) or negative control
siRNA (D-001206-13-05) obtained from Thermo Fisher
Scientiﬁc (Waltham, MA) using Lipofectamine 2000
(Invitrogen, Grand Island, NY) for 4 hours. The expression
of E2f1 and Cdc25a at RNA and protein levels were
measured 48 hours post-transfection.
Dihydroethidine Staining
For assessing superoxide anions, frozen optimal cutting tem-
perature compound embedded liver sections were incubated
with 10 mmol/L dihydroethidine (DHE) (Sigma-Aldrich) atThe American Journal of Pathology - ajp.amjpathol.org37C for 30 minutes and counter stained with DAPI (Santa
Cruz Biotechnology, Dallas, TX).21 The red ﬂuorescence of
DHE oxidized by superoxide anions and blue ﬂuorescence of
DAPI-stained nuclei were detected by an Olympus FV1000
Filter confocal microscope (Olympus, Center Valley, PA).
Statistical Analysis
Real-time RT-qPCR analysis was performed in triplicate. The
data were presented as means  SD. Most of the experiments
were repeated twice. Statistical signiﬁcance was calculated with
theStudent t-test,with aPvalueof<0.05considered signiﬁcant.1721
Hsu et alResults
Early Onset of Hepatobiliary Cysts at Preneoplastic
Stage in miR-122 LKO Mice on Exposure to DEN
To examine the pathological consequence of miR-122 loss
on challenge with a hepatocarcinogen DEN, we used1722recently characterized LKO mice harboring liver-speciﬁc
miR-122 ablation.15 LKO and littermate control mice were
injected with a single dose of DEN at P14 when it acts as a
complete carcinogen.18 Real-time RT-qPCR RT-qPCR
analysis showed that the hepatic miR-122 level was barely
detectable (approximately 0.7% of the wild-type level) at
this age (Supplemental Figure S1A).Figure 1 Diethylnitrosamine (DEN)-treated
liver-speciﬁc miR-122 knockout (LKO) mice devel-
oped liver cysts and hepatocellular carcinoma
(HCC)-like nodule at week 25 post-DEN exposure.
A: Representative images of the livers from DEN-
injected control (ﬂoxed) and miR-122 LKO mice
exhibited appearance of cysts only in LKO mice. B:
The incidence of cysts developed in control (n Z
5) and LKO (n Z 6) mice. C: T2-weighted MRI of
liver in control and LKO mice with transverse sec-
tion. Arrows denote cysts. D: Quantiﬁcation of
cyst area. E, G, and I: H&E staining of microscopic
tumor (T) and surrounding liver tissues from DEN-
injected control and LKO mice. F: The inﬂammation
index of liver tissues from DEN-injected control (n
Z 5) and LKO (nZ 6) mice. The scoring method is
described in Materials and Methods. H and J: The
incidences of HCC (H) and hepatocellular adenoma
(HA) (J) developed in control (n Z 5) and LKO (n
Z 6) mice. K: IHC with Afp antibody showed that
the tumor in LKO mice is predominantly Afp posi-
tive. L: Quantiﬁcation of the number of Afp-
positive cells. Original magniﬁcation: 100 (E),
200 (G), and 400 (I). Scale bars: 400 mm (E);
80 mm (G and L); 20 mm (I); and 10 mm (K, inset).
**P  0.01.
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DEN Induces Liver Cyst in miR122 LKOFive DEN-injected mice of each genotype were sacriﬁced
and analyzed at week 25 post-DEN treatment when dysplastic
nodules are typically formed.23 Notably, LKO mice devel-
oped macroscopic cysts in 83% of liver lobes, which were not
visible in DEN-exposed control mice (Figure 1, A, B and D).
Intrahepatic cysts, visualized as bright spots by T2-weighted
MRI, were only detected in LKO mice (Figure 1C). H&E
staining showed that both LKO and control mice developed
steatosis, whereas hepatitis was developed only in LKOmice
(Figure 1, E and F). Microscopic tumors were developed in
both genotypes. However, LKO mice predominantly devel-
oped Afp-positive HCC (Figure 1, G, I, and K; Figure 1H
shows the incidences of HCC), whereas control mice only
developed hepatocellular adenoma (HA) (Figure 1, G, I, and
K; Figure 1J shows the incidences of HA). HA andHCCwere
characterized based on the establishedmorphological criteria,
including existence of trabecular growth pattern of cancer
cells, vascular invasion of tissues, malignancy of proliferating
cells, expression of a-fetal protein.24,25 Saline-injected LKO,
but not control,mice developedmicrosteatosis and hepatitis at
25 weeks, but none developed tumors (data not shown). Up-
regulation of several protumorigenic factors such as c-Jun,
Ctnnb1, and several miR-122 targets, eg, Adam10, Ndrg3,
and Mapkapk2 in DEN-injected livers compared to controlsThe American Journal of Pathology - ajp.amjpathol.org(Figure 2A) correlated with increased susceptibility of LKO
mice to form dysplastic foci. Many of these genes were also
up-regulated or not changed in untreated LKO livers
compared to control livers (Supplemental Figure S1D) and
were further elevated in DEN exposed livers.
The microscopic tumors developed in DEN-treated LKO
mice were more proliferative than those in control mice as
demonstrated by ﬁvefold more Ki-67epositive cells (a
representative image is shown in Figure 2B). Moreover, IHC
analysis with anti-CD34 antibody revealed abundance of
vascular endothelial cells, both in the tumor and benign liver
tissues of LKO mice, compared to that in control mice at 25
weeks post-DEN injection (Figure 2, C and D). Notably,
more CD34-positive cells accumulated in the portal area of
LKO mice compared to controls (Figure 2D). Sirius red
staining showed that DEN-injected LKO livers exhibited
severe ﬁbrosis compared to control mice (Figure 2E).
Increased expression of insulin-like growth factor 2 (Igf2),
vascular endothelial growth factor-a (Vegf-a), and Vimentin
correlated with pronounced angiogenesis in LKO livers,
whereas up-regulation of Ctgf correlated with enhanced
ﬁbrosis in LKO livers (Figure 2, A and F). Notably, the
expression of hepatic Vimentin and Ctgf (Supplemental
Figure S1D) were elevated in saline-injected LKO miceFigure 2 LKO mice exhibited more prolifera-
tive, vascular, and ﬁbrotic livers at 25 weeks
following diethylnitrosamine (DEN) treatment. A:
Real-time RT-qPCR analysis (SYBR Green assay) of
several tumor-promoting genes, including miR-122
targets, in control and LKO livers at 25 weeks post-
DEN injection. Relative expression of indicated
proteins in DEN-injected control livers was arbi-
trarily set at one. B: Ki-67 IHC revealed that
microscopic tumors in LKO mice are more prolif-
erative than the controls. C and D: IHC of liver
tumor (C) and normal matching liver (D) with CD34
antibody. CD34-positive cells were more abundant
in the tumor and livers of LKO mice compared to
those in control mice. Arrows indicate CD34-
positive cells in portal area, which are stained
dark brown. E: LKO livers developed more ﬁbrosis
on DEN exposure compared to controls as demon-
strated by Sirius red staining of ﬁbrotic tissues. F:
Western blot analysis of Ctgf, Vimentin, and Gapdh
in liver extracts of mice at 25 weeks post-DEN in-
jection and saline injection. G: Representative
images of control and LKO liver coveredwithmultiple
cysts (arrows) and tumors (arrowhead) at week 44
following DEN injection.H: Representative images of
CK19 IHC of liver section of control and LKO mice
bearing cysts at week 25 post-DEN injections. Cells
stained dark brown are CK-19epositive cells. Scale
bars: 80mm(B); 25mm(B, inset); 50mm(C); 100mm
(D and E).
1723
Hsu et aland increased further on DEN exposure (Figure 2A). Taken
together, these results indicate that hepatic loss of miR-122
promoted angiogenesis, and ﬁbrosis at the pre/neoplastic
stage after single DEN exposure at the postnatal stage.
Hepatic Cdc25a, which Promotes Cystogenesis, Is
Up-Regulated in miR-122 LKO Mice on DEN Exposure
Formation of cysts at the preneoplastic stage only in DEN-
treated LKO mice and their dramatic spread in all liver lobes
with time (Figure 2G) suggested for us to characterize these
cysts. IHC analysis showed that these liver cysts were lined
with CK19-positive cholangiocytes (Figure 2H). We
focused our attention to Cdc25a because it has recently been
shown to play a causal role in hepatobiliary cyst formation
by inducing the proliferation of cystic cholangiocytes.26
Indeed, both RNA and protein levels of Cdc25a increased
more than twofold in DEN-injected LKO mice compared to
control mice (Figure 3, A and B).
Next, we sought to understand the mechanism of up-
regulation of Cdc25a in DEN-injected LKO mice. First, we
measured miR-15a, because its down-regulation is reported
to contribute to hepatic cystogenesis by up-regulating
Cdc25a.27 However, expression of miR-15a and miR-16
that can target Cdc25a was not signiﬁcantly altered in LKO
livers compared to controls (Supplemental Figure S1B).
Because TargetScan28 predicted Cdc25a as a potential
miR-122 target (Figure 3A), we performed a luciferase assay
after cloning the Cdc25a 30-UTR into psiCHECK2 vector.
However, miR-122 did not affect reporter activity driven
by Cdc25a 30-UTR (Figure 3A), suggesting that it is not a1724direct target of miR-122. Moreover, real-time RT-qPCR
(Figure 3B) and Western blot (data not shown) analyses did
not show up-regulation of Cdc25a in saline-injected LKO
livers, suggesting that DEN exposure indirectly activated the
Cdc25a gene in these mice. Indeed, real-time RT-qPCR
analysis conﬁrmed up-regulation of Cdc25a primary tran-
script (hnRNA) and mRNA at comparable levels (approxi-
mately two- to threefold) at preneoplastic stage in LKO livers
(Figure 3B), indicating its transcriptional induction.
We then attempted to elucidate the mechanism of induction
of Cdc25a in DEN-exposed LKO livers. E2f1, an important
cell-cycle regulator, has been reported to activate the Cdc25a
gene.29 We hypothesized that up-regulation of E2f1 in DEN-
treated LKO livers might play a causal role in the induction
of Cdc25a, thereby promoting cyst formation. Indeed, E2f1
was up-regulated in DEN-exposed LKO livers at the preneo-
plastic stage (Figure 3, C and D), and siRNA-mediated
knockdown of E2f1 reduced the Cdc25a level both at the
mRNA (25%) and protein levels (40%) in Hepa cells
(Figure 3, E and F). Notably, siRNA-mediated knockdown of
E2f1 protein level (80%) was more pronounced than its RNA
level (40%). Taken together, these results suggest that E2f1-
mediated activation of Cdc25a is one of the mechanisms
involved in cystogenesis in LKO mice on DEN exposure.
DEN-Induced Liver Damage and HCC Incidence Are
Signiﬁcantly Higher in LKO Mice
At week 35 following DEN injection, 14 mice of each ge-
notype were sacriﬁced to assess tumor burden. Although the
total number of macroscopic tumors developed in mice wasFigure 3 E2f1-mediated transcriptional induc-
tion of Cdc25a may induce liver cysts in LKO mice.
A: Renilla luciferase activity (LUC2) produced from
wild-type or mutant Cdc25a 30-UTR reporter plas-
mids or empty vector normalized to ﬁreﬂy luciferase
activity (LUC1) produced from the same plasmid
after transfection into Hepa cells together with
negative control (NC) RNA or miR-122 mimic. Error
bars represent standard deviations derived from
three independent experiments. B: Both pre-mRNA
(hnRNA) and mRNA are up-regulated at similar level
in DEN-injected LKO livers. Real-time RT-qPCR
analysis of Cdc25a mRNA and hnRNA in livers (nZ
5) was performed. The data were normalized to
Gapdh RNA level. C: Western blot analysis of liver
extracts with speciﬁc antibodies at week 25 post-
DEN injection. D: Quantiﬁcation of the protein
signals. mRNA (E) and protein levels (F) of Cdc25a
and E2f1 in Hepa cells transfected with 60 nmol/L
negative control or E2f1 siRNA (nZ 3). The results
were normalized to Gapdh level. *P  0.05, **P 
0.01, and ***P  0.001.
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 LKO mice exhibited higher tumor
burden and hepatobiliary injury at week 35 post-
diethylnitrosamine (DEN) injection. A: Number of
macroscopic tumors developed in mice. B: Total
weight of tumors harvested from DEN-injected
mice. C: Liver/body weight ratio of DEN-injected
mice. DeF: Serological analysis of DEN-injected
mice. G: Survival curve of female LKO and control
mice injected with 25 mg/kg DEN on P14. Because
all mice died at the end of the study, the two-
sample t-test was used to test the survival differ-
ence. The Kaplan-Meier survival curves were
generated to display the results. nZ 9 for control
(cree) mice and nZ 10 for LKO (creþ) mice. ALT,
alanine aminotransferase; ALP, alkaline phospha-
tase; GGT, gamma-glutamyltransferase.*P  0.05,
**P  0.01, and ***P  0.001.
DEN Induces Liver Cyst in miR122 LKOnot signiﬁcantly different between the two genotypes
(Figure 4A), the total tumor weight (approximately ninefold,
P Z 0.015) was higher in the mutant mice (Figure 4B),
suggesting faster tumor growth in LKO mice. Twofold in-
crease in liver to body weight ratios (Figure 4C) and
elevated serum alanine aminotransferase (ALT) (approxi-
mately 1.7-fold), gamma-glutamyltransferase (GGT)
(approximately ﬁvefold) and alkaline phosphatase (ALP)
(approximately ﬁvefold) (Figure 4, DeF) levels indicated
excessive liver damage in LKO mice compared to controls.
Elevation of serum ALP is a characteristic of animals
depleted of miR-122 by injecting locked nucleic acide
modiﬁed anti-sense oligonucleotides30 or genetic abla-
tion,15,16 even without carcinogen exposure.
As shown in Figure 5A, LKO mice at week 35 post-
DEN exposure developed larger tumor and numerous
cysts, whereas control mice developed only smaller tu-
mors. MRI of a few mice demonstrated bigger tumors and
cysts in LKO mice compared to controls (a representative
image is shown in Figure 5B). Histological analysis of
H&E-stained sections demonstrated that 71% (10 of 14) of
LKO mice developed HCC as opposed to only 21.4% (3 of
14) of control mice formed HCC (Figure 5, C and F). At 35The American Journal of Pathology - ajp.amjpathol.orgweeks, 86% (12 of 14) of LKO mice developed macro-
scopic liver cysts, as opposed to none in control mice
(Figure 5, D and F). Analysis of the cystic ﬂuid from a
few mice showed high levels of ALT, GGT, ALP, and
bile acids (data not shown). CK-19epositive cholangi-
ocarcinoma was detected in two LKO mice (Figure 5,
D and F). By contrast, the majority of liver tumors
developed in control mice were hepatocellular adenoma
(Figure 5C). BrdU incorporation, an index of proliferation,
was approximately fourfold higher (P Z 0.03) in tumors
developed in LKO mice than those in control mice
(Figure 5E). Metastatic lung tumors were detected only in
three LKO mice (data not shown).
Almost all DEN-injected female LKO mice developed
tumors and cysts with age and exhibited reduced survival
compared with the control mice, as evident from the death
of 6 of 10 LKO mice within 12 months of DEN injection,
whereas all control mice were still alive (Figure 4G). The
tumor weight, liver damage, and cyst formation were
signiﬁcantly higher in female LKO mice compared to con-
trols (data not shown). Collectively, these results demon-
strate that loss of miR-122 enhances susceptibility of mice
to a liver carcinogen.1725
Hsu et alUp-Regulation of Several Oncogenic Targets of
miR-122 Including Axl, a Receptor Tyrosine Kinase,
Correlates with Enhanced Susceptibility of LKO Mice to
Hepatocarcinogenesis on DEN Exposure
Previously, we have shown that loss of miR-122 induces up-
regulation of genes involved in cell proliferation, including
fetal genes in liver.15 Several of these genes are conﬁrmed as
direct targets of miR-122.12,31 To understand the role of these
targets in promoting DEN-induced tumorigenesis, we
measured their expression in tumors developed in control and
LKO mice by immunoblotting. The results showed that three
miR-122 targets Adam10, Ccng1, and Srf were signiﬁcantly
increased by approximately 2-, 2.5-, and 2-fold, respectively,
in LKO tumors compared to controls (Figure 6, A and B).
Elevation of Afp (threefold), a fetal gene and a marker of
HCC, in all LKO tumors compared to those in controlsFigure 5 Loss of miR-122 in liver promoted hepatocellular carcinoma (HCC
Representative images of livers showing bigger macroscopic tumors and cysts
T2-weighted MRI image of liver with transverse section. Arrowheads indicate cys
adenoma (HA) and HCC identiﬁed in control and LKO mice, respectively. D: H&E sta
represents CK-19epositive cholangiocytes. E: IHC of liver tumors with BrdU antib
BrdU-positive cells. The BrdU-positive cells in control and LKO liver tumors were
pathological features, including HCC, CC, HA, and cysts in livers harvested from DE
50 mm (C); 50 mm (D, left panel, inset); 500 mm (D, right panel); 20 mm (E).*
1726correlated with the histopathological analysis (Figure 5, C
and F). As expected, both E2f1 and Cdc25a were also up-
regulated in LKO tumors (Figure 6, A and B).
Axl, a receptor tyrosine kinase, is up-regulated in different
neoplasms, including HCC, and exhibits characteristics of an
oncogene.32 It is also a predicted target of miR-122 in mouse
(Figure 6C) and human (Table 2). Microarray analysis
showed an approximately 1.8-fold (P Z 0.001) up-
regulation of Axl in LKO livers, which was conﬁrmed by
real-time RT-qPCR (Figure 6D) and Western blot analysis
(Figure 6, E and F); we were curious to know whether Axl
level was elevated in DEN-induced LKO tumors. Indeed, the
Axl protein level increased 1.9-fold (P Z 0.0001) in LKO
tumors compared to controls (Figure 6, A and B).
We next investigated whether Axl is a true target of
miR-122 by measuring Axl-30-UTRedriven renilla luciferase.
Relative luciferase activity (renilla to ﬁreﬂy) was reduced by) and liver cysts at week 35 postdiethylnitrosamine (DEN) exposure. A:
developed in LKO mice. Arrows indicate cysts; arrowhead, tumors. B:
ts; arrows, tumors. C: Representative H&E stained images of hepatocellular
ining of cholangiocarcinoma (CC) and cysts identiﬁed in LKO mice. The inset
ody in mice injected with BrdU 3 hours before euthanasia. Arrows indicate
quantiﬁed and presented in the right panel. F: The incidence of indicated
N injected control (nZ 14) and LKO (nZ 15) mice at 35 weeks. Scale bars:
P  0.05.
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Figure 6 Up-regulation of genes involved in
oncogenesis, including miR-122 targets, in tumors
developed in LKO mice. A: Western blot analysis of
indicated proteins in tumor extracts from control
and LKO mice at week 35 postdiethylnitrosamine
(DEN) injections. B: Quantitative representation of
the Western blot data in A. The band intensity was
quantiﬁed using ImageJ software version 1.46r
(NIH, Bethesda, MD), and the data were normal-
ized to Gapdh level. Fold increase in indicated
proteins in LKO tumors compared to control tumors
are presented. C: Predicted miR-122 binding site in
the 30-UTR of Axl. DeF: The hepatic expression of
Axl in 10-week-old control and LKO mice was
determined by real-time RT-qPCR (D) and Western
blot analysis (E and F). G: Axl is a target of miR-
122. Renilla luciferase activity (LUC2) produced
from the wild-type or mutant Axl 30-UTR reporter
plasmids normalized to that of ﬁreﬂy luciferase
(LUC1) after transfecting Hepa cells with the
respective plasmid along with 25 nmol/L negative
control RNA (NC) or miR-122 mimic. Error bars
represent standard deviations derived from three
independent experiments. mRNA (H) and protein
(I) levels of Axl in Hep3B cells transfected with
negative control RNA or miR-122 mimic. J: miR-
122 level normalized to RNU6B was measured by
real-time RT-qPCR (n Z 3). *P  0.05,
**P  0.01, and ***P  0.001.
DEN Induces Liver Cyst in miR122 LKOapproximately 40% (P Z 0.007) in cells cotransfected with
the reporter (LUC-Axl 30-UTR) and miR-122 compared to
those transfected with negative control RNA, which was
abrogated after deletion of the miR-122 cognate site from the
reporter plasmid (LUC-Axl del 30-UTR) (Figure 6G).
Furthermore, ectopic miR-122 expression in Hep3B cells that
do not express miR-122 reduced Axl mRNA expression both
at the RNA (approximately 60%) and protein (approximately
40%) levels (Figure 6, HeJ). Similar results were observed in
Hepa cells (Supplemental Figure S2).
DEN Exposure Induces Oxidative Stress and Increases
Expression of Proinﬂammatory Cytokines in miR-122
LKO Mice
DEN is enzymatically converted to reactive ethyldiazonium
ion, which causes DNA damage by reacting with DNA
bases. DEN is known to cause oxidative stress.33 To
examine whether LKO mice are sensitive to DEN-induced
oxidative stress, we treated LKO mice with DEN and
measured oxidative stress in frozen tissue sections by DHE
staining, which reacts with superoxide anion. LKO livers
exhibited more oxidative stress for 12 hours following DEN
treatment, as demonstrated by the intense red ﬂuorescence
with DHE compared to controls (Supplemental Figure S3).
Furthermore, much higher induction of IL6 (2.1-fold in
control versus 11.8-fold in LKO), tumor necrosis factor-a
(TNF-a) (3.8-fold in control versus 17.4-fold in LKO), andThe American Journal of Pathology - ajp.amjpathol.orgIL1b (1.4-fold in control versus 6.4-fold in LKO) in LKO
livers exposed to DEN for 12 hours (Figure 7, AeC)
occurred in mutant mice. Increased production of superox-
ide anion and induction of proinﬂammatory cytokines
immediately after DEN injection suggest that LKO mice are
more susceptible to genotoxic stress.Discussion
Protective Role of miR-122 against a Chemical
Carcinogen
miR-122 exhibits pleiotropic functions in mammals.4
Although it is not essential for liver development, it is
involved in lipid homeostasis and maintenance of hepatic
function in adult mice.15,16 However, it is still not clear how
miR-122 deﬁciency may affect the development of liver
tumor with the combination of other risk factors, such as
chemical carcinogens. DEN is a carcinogen used frequently
for induction of HCC in mice.21 Here, we have demon-
strated that loss of miR-122eexpedited DEN-induced HCC
development in mice. DEN-injected LKO mice exhibited
larger tumor mass and higher incidence of HCC compared
to DEN-injected control mice. Carcinogen-induced liver
damage was also more pronounced in LKO mice. Notably,
DEN exposure on P14 also caused liver tumor development
in female LKO mice that were found to be resistant to
spontaneous tumorigenesis.15 However, unlike tumors1727
Table 2 RNA22 Algorithm Predicts Existence of Multiple miR-122 Complementary Sites in 30-UTR of Both Spliced Variants of Human Axl
mRNAs
Variant Position Predicted target site Targeting miRNA sequence
#1 ENST00000359092
hsa_miR_122 4152 50-TTTCAAGGCACTCTAGATTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
hsa_miR_122 4089 50-AGATTCTAGATCAGATGCTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
hsa_miR_122 2893 50-ACTGCCACTGGGGAAAACTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
#2 ENST00000301178
hsa_miR_122 4179 50-TTTCAAGGCACTCTAGATTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
hsa_miR_122 4116 50-AGATTCTAGATCAGATGCTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
hsa_miR_122 2920 50-ACTGCCACTGGGGAAAACTCCA-30 50-TGGAGTGTGACAATGGTGTTTG-30
Hsu et aldeveloped in liver-speciﬁc Ctnnb1 knockout mice,34 those
produced in LKO mice were not signiﬁcantly repopulated
with miR-122epositive hepatocytes that escaped Cre-
mediated deletion (Supplemental Figure S1C). Interest-
ingly, DEN exposure caused liver cyst formation only in
LKO mice, irrespective of the sex. Cysts do not commonly
occur in human HCC patients, unless there is internal ne-
crosis caused by certain therapies such as radiofrequency
ablation.35 To the best of our knowledge, there is no report
about the cyst formation induced just by a single DEN in-
jection in mice, except in a few cases with continuous
treatment of DEN at high doses for several weeks36 or in
combination with pentachlorophenol.37 The present study is
the ﬁrst to observe the signiﬁcant effect of miR-122 deﬁ-
ciency on hepatic cyst formation.
One crucial factor in hepatocarcinogenesis is chronic he-
patic inﬂammation,38 which is induced by the loss of
miR-122 and is exhibited in the liver of DEN-treated LKO
mice. We have shown that the activation of the Ccl2eCcr2
axis plays a causal role in hepatic inﬂammation in these
mice.15 However, we cannot rule out the involvement of
additional mechanisms, such as hypoxia, which is known to
induce sterile inﬂammation through the activation of proin-
ﬂammatory gene programs, such as TLR-induced NF-kB
signaling and chemokine secretion (reviewed in39). Simul-
taneously, certain hypoxia-induced genes, such as HIF, can
protect cells from injury by inhibition of apoptosis orFigure 7 Postnatal dihydroethidine (DHE) exposure promoted oxidative stress
IL-6, TNF-a, and IL-1b were determined by real-time RT-qPCR in livers of control an
value of 1. *P  0.05.
1728induction of adenosine signaling.40,41 Therefore, it will be
intriguing to see whether hypoxia can regulate hepatic
inﬂammation through its transcriptional regulation of
miR-122. Previously, it was reported that miR-122 was
down-regulated by hypoxia,42 which implies a possibility
that the miR-122 deﬁciencyeinduced inﬂammation could be
a result of hypoxia.
The Role of Cdc25a in Cyst Formation
To explore the mechanism of DEN-induced cyst develop-
ment in LKO mice, we looked for potential target genes that
are known to be involved in cystogenesis in liver. Cdc25a is
one such candidate gene that has recently been shown to play
a pivotal role in hepatic and renal cyst formation in rodent
models.37 Interestingly, Cdc25a was up-regulated in DEN
injected LKO mice compared to the controls. However,
expression miR-15a that targets Cdc25a and affects hepatic
cystogenesis in polycystic kidney disease27,43 remained un-
altered in cyst-bearing LKO mice compared to DEN-injected
control mice (data not shown). Prediction of Cdc25a as a
direct target of miR-122 by TargetScan28 led us to hypoth-
esize that miR-122 deﬁciency resulted in activation of the
Cdc25a gene in LKO mice. However, the inability of lucif-
erase assay to conﬁrm Cdc25a as a direct target of miR-122
and up-regulation of its primary transcript suggested tran-
scriptional activation of Cdc25a in LKO mice at week 25and induced proinﬂammatory cytokines in LKO livers. AeC: mRNA levels of
d LKO mice. The respective levels in saline injected controls were assigned a
ajp.amjpathol.org - The American Journal of Pathology
DEN Induces Liver Cyst in miR122 LKOpost-DEN injection. We focused on E2f1, a known activator
of the Cdc25a gene. Indeed, E2f1 was signiﬁcantly elevated
in DEN-exposed LKO livers, and siRNA-mediated depletion
of E2f1 reduced the Cdc25a level in hepatic cells. Our data
showed that DEN-induced oxidative stress is higher in LKO
mice (Supplemental Figure S3) and may result in liver injury
and compensatory proliferation of damaged hepatocytes,
which is signiﬁcantly higher in these mice compared to the
control mice due to the activation of several growth pro-
moters, including Igf2 (Figure 2A) and c-Myc.15 E2f1, a cell-
cycle promoter, is up-regulated in these proliferating cells,
thereby increasing expression of Cdc25a. Therefore, it is
likely that Cdc25a is one of the factors that contribute to cyst
formation in LKO mice. However, we cannot rule out the
involvement of additional factor(s) that might contribute to
cystogenesis. Indeed, expression of two genes, Sec63 and
Pkrcsh that encode hepatocystin, are down-regulated in LKO
livers (data not shown). Loss of expression of these genes due
to germline or somatic mutation is associated with polycystic
liver disease in humans, characterized by multiple ﬂuid-ﬁlled
cysts in the liver,44,45 as observed in LKO mice exposed to
DEN.
The Role of Axl, a Novel Target of miR-122, in
Oncogenesis
Identiﬁcation of Axl, a receptor tyrosine kinase, as a target of
miR-122 merits discussion. Axl was ﬁrst identiﬁed in patients
with chronic myelogenous leukemia,46 and correlation be-
tween its overexpression, metastasis, and poor prognosis was
subsequently reported in different malignancies.47 Axl is a
downstream target of several key signaling pathways, eg,
Tgf-b1, Hippo, and Vegf-A, and promotes oncogenesis by
facilitating proliferation, migration, invasion, and angiogen-
esis and inhibiting apoptosis. Abundance of miR-122 is likely
to be responsible for the suppression of Axl in the liver, and its
up-regulation in tumors might play a causal role in producing
highly invasive tumors in LKO mice. Interestingly, Axl is
also elevated in tumors developed spontaneously in
miR-122edeﬁcient livers; Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo, accession number GSE31731). It
would be of interest to investigate whether small molecule
inhibitors of Axl can impede tumor growth in LKO mice. So
far, studies from several laboratories, including ours, identiﬁed
several tumor-promoting genes as direct targets of miR-122,
including Ccng1, Axl, Adam10, and Srf. Among these genes,
Axl and Adam10 were both critical in the tumor migration and
invasion, whereas Ccng1 and Srf were both involved in pro-
liferation of tumor cells. Through de-repression of these genes,
loss of miR-122 in liver may promote a subset of hepatocytes
to proliferate more aggressively than those in control mice
during compensatory proliferation after liver damage induced
by genotoxic chemicals such as DEN. On the basis of our
results, we propose a model (Supplemental Figure S4)
describing the consequence of miR-122 loss in DEN-induced
liver pathogenesis.The American Journal of Pathology - ajp.amjpathol.orgIn conclusion, our data show a novel function of miR-122
in suppressing DEN induced cystogenesis and HCC. These
results further extend our knowledge about the protective
role of miR-122 in the liver from genotoxic carcinogens. In
the future, it would be of interest to examine whether in-
hibitors of Cdc25a and Axl can reverse the deleterious effect
of the carcinogen.Acknowledgments
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